Roche Holding : COVID-19 hits Roche harder than expected in Q2
>H1 2020 results: 2-3% below expectations - Roche reported disappointing H1 results that were between -2% and -3% below forecasts for sales, EBIT and EPS (cf. table). In detail, everything is not quite as good as expected. The COVID-19 pandemic, the negative effects of which exceeded the positive effects in Q2, seems to be the main explanation. All told, H1 sales growth was +1% at constant currencies, but Roche disclosed monthly data for Q2 and this showed an impressi...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.